ALFA Finder| Revenue growth | Consolidated +45.7%; ex-Coris +22.1%. |
|---|---|
| Margins | Coris EBITDA loss cut 45% to EUR304K. |
| Order book | Coris HAT EUR1.41M confirmed; Middle East order inflow. |
| Demand visibility | Coris HAT order EUR1.41M due Dec-26. |
| Management confidence | Hedged; MDx growth 'hoped', geopolitics cited. |
Growth
Consolidated revenue +45.7% (base effect: Coris only from 29-Aug-25). Ex-Coris revenue +22.1%, PAT ₹3,269L (+16.4%).
Outlook
MDx FY27 growth 'hoped' at 15–20%. Coris FY27 sales guided 10–15% with slight positive EBITDA. US FDA RESIST-5 in 1–2 years; US sales from FY28.
Risks
Geopolitical tension delaying exports and orders. Chinese competition de-growing Coris non-AMR products. Liberal credit policy raising debtors. Flu-spike sales non-recurring.
Investor Presentation filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,341.55
- Market cap
- ₹1,151 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹59.93 Cr
- P/E (TTM)
- 19.6×Sector 35.1×
- Promoter holding
- 40.95%+0.00% QoQ
- FII holding
- 2.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Q2 FY27 Results: Net Profit ₹18 Cr, Up 20.0% YoY
3B BlackBio Dx Ltd reported revenue from operations of ₹48.3 Cr (+42.5% YoY) and net profit of ₹18 Cr (+20.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18 Cr · +20.0% YoY
3B BlackBio Dx Board Meeting Date
3B BlackBio Dx Ltd has scheduled a board meeting for November 13, 2026. The board will consider unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
3B BlackBio Dx Other Announcement
The company submitted its quarterly shareholding pattern as per Regulation 31(1)(b) of the SEBI Listing Regulations for the period ending September 30, 2026.
3B BlackBio Dx Other Announcement
3B BlackBio DX Limited announced the re-appointment of Mrs. Mithla Dubey as a Non-Executive Non-Independent Director. Her re-appointment follows retirement by rotation.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd shareholders approved a dividend of Rs. 5.00 per share at its 54th AGM. The company also presented an investor overview of its FY26 performance.
3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.